{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:01:56Z","timestamp":1763017316842},"reference-count":20,"publisher":"Elsevier BV","issue":"4","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.thromres.2013.08.017","type":"journal-article","created":{"date-parts":[[2013,8,30]],"date-time":"2013-08-30T19:17:56Z","timestamp":1377890276000},"page":"433-436","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Non-therapeutic anti-Xa levels in medical patients receiving anticoagulant therapy with enoxaparin"],"prefix":"10.1016","volume":"132","author":[{"given":"Allan","family":"Ramos-Esquivel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lizbeth","family":"Salazar-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2013.08.017_bb0005","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1161\/01.CIR.100.15.1602","article-title":"Assessment of the treatment effect of enoxaparin for unstable angina \/ non-q-wave myocardial infarction. TIMI 11B-ESSENCE Meta-Analysis","volume":"100","author":"Antman","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2013.08.017_bb0010","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S0029-7844(03)00340-5","article-title":"A longitudinal study of maternal dose-response to low molecular weight heparin in pregnancy","volume":"101","author":"Sephton","year":"2003","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.thromres.2013.08.017_bb0015","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1001\/archinte.162.22.2605","article-title":"Is impaired renal function a contraindiciation to the use of low-molecular-weight heparin?","volume":"162","author":"Nagge","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.thromres.2013.08.017_bb0020","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00277-011-1208-1","article-title":"Non therapeutic anti-FXa levels are common among ward patients treated with enoxaparin","volume":"90","author":"Saliba","year":"2011","journal-title":"Ann Hematol"},{"key":"10.1016\/j.thromres.2013.08.017_bb0025","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(02)07920-5","article-title":"Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors","volume":"359","author":"D\u00f6rffler-Melly","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2013.08.017_bb0030","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0049-3848(02)00028-2","article-title":"Antifactor Xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparin","volume":"105","author":"Mayr","year":"2002","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2013.08.017_bb0035","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1097\/01.CCM.0000059725.60509.A0","article-title":"Prophylactic anticoagulation with enoxaparin: is the subcutaneous route appropriate in the critically ill?","volume":"31","author":"Priglinger","year":"2003","journal-title":"Crit Care Med"},{"key":"10.1016\/j.thromres.2013.08.017_bb0040","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1592\/phco.24.17.1793.52344","article-title":"Antifactor Xa levels in four patients with burn injuries who received enoxaparin to prevent venous thromboembolism","volume":"24","author":"Yogaratnam","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.thromres.2013.08.017_bb0045","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1161\/01.CIR.0000136830.65073.C7","article-title":"AntiXa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin","volume":"110","author":"Montalescot","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2013.08.017_bb0050","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1055\/s-0038-1651032","article-title":"The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparin low molecular weight heparin to prevent deep vein thrombosis after hip replacement","volume":"62","author":"Levine","year":"1989","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2013.08.017_bb0055","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1182\/blood.V78.9.2337.2337","article-title":"Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin","volume":"78","author":"Nieuwenhuis","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2013.08.017_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/BCR.0b013e318204b346","article-title":"Enoxaparin and antifactor Xa levels in acute burn patients","volume":"32","author":"Hsin","year":"2011","journal-title":"J Burn Care Res"},{"key":"10.1016\/j.thromres.2013.08.017_bb0070","first-page":"35","article-title":"Low molecular weight heparins: practical considerations","volume":"34","author":"Kessler","year":"1997","journal-title":"Semin Hematol"},{"key":"10.1016\/j.thromres.2013.08.017_bb0075","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0272-2712(18)30347-0","article-title":"Contemporary laboratory monitoring of low molecular weight heparins","volume":"15","author":"Samama","year":"1995","journal-title":"Clin Lab Med"},{"key":"10.1016\/j.thromres.2013.08.017_bb0080","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0248-8663(00)00300-3","article-title":"H\u00e9parines de bas poid mol\u00e9culaire et risque h\u00e9morragique chez le malade \u00e2g\u00e9","volume":"22","author":"Franco","year":"2001","journal-title":"Ver M\u00e9d Internet"},{"key":"10.1016\/j.thromres.2013.08.017_bb0085","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/clpt.1981.53","article-title":"Heparin kinetics: variables related to disposition and dosage","volume":"29","author":"Cipolle","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.thromres.2013.08.017_bb0090","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00007691-200406000-00015","article-title":"Effect of renal function oh the pharmacokinetics of enoxaparin and consequences on dose adjustment","volume":"26","author":"Hulot","year":"2004","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.thromres.2013.08.017_bb0095","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1067\/mhj.2002.120774","article-title":"TIMI 11a investigators. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST segment elevation acute coronary syndrome","volume":"143","author":"Becker","year":"2002","journal-title":"Am Heart J"},{"key":"10.1016\/j.thromres.2013.08.017_bb0100","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1538-7933.2004.00647.x","article-title":"Is laboratory monitoring of low-molecular-weight-heparin therapy necessary? Yes","volume":"2","author":"Harenberg","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2013.08.017_bb0105","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.1016\/S0021-9258(17)35610-7","article-title":"Neutralization of heparin-related sacharides by histidin-rich glycoprotein and platelet factor 4","volume":"261","author":"Lane","year":"1986","journal-title":"J Biol Chem"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384813003721?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384813003721?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T06:39:31Z","timestamp":1646462371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384813003721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0049384813003721"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2013.08.017","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-therapeutic anti-Xa levels in medical patients receiving anticoagulant therapy with enoxaparin","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2013.08.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}